Study of 2LPAPI® on the Clearance of Genital HR-HPV Infections.

Inclusion Criteria:

• Women 25-45 years,

• Women of childbearing age under effective contraception,

• Patient with last cytology less than 3 years and normal or not more than LSIL or CINI at the histology,

• Patient with current cytology presenting normal, ASC-US, AGUS, LSIL, ASC-H, AGC orLSIL+ASC-H results or current diagnosis of CIN I at the histology,

• Patient with HR-HPV diagnosis at the current cervical collection,

• Patient reporting a current stable sexual relationship (steady sexual partner duringstudy duration),

• Patient having faculties to understand and respect the constraints of the study,

• Signature of the Informed Consent Form.

Exclusion Criteria:

• Pregnant or breastfeeding woman,

• Patient presenting HSIL diagnosis at the cytology or CIN II or CIN III diagnosis atthe histology,

• Patient having received HPV vaccination in the last month,

• Patient previously subject to total hysterectomy,

• Patient under immunotherapy (including immunosuppressive treatment) ormicro-immunotherapy received during last previous 6 months,

• Patient with known lactose intolerance,

• Patient who participated in a clinical study in the previous 3-months' period,

• Patient who is not sufficiently motivated to engage in a follow-up period of 12months, or likely to travel or to move before the end of the study,

• Patient with severe immunodeficiency disease requiring long term treatment (*) orunder chemotherapy or radiotherapy,

• Patient under listed homeopathic or phytotherapy treatment (see protocol),

• Patient using or addicted to recreational drugs.

(*) important renal or respiratory insufficiency, transplanted or grafted patients, HIV/AIDS, terminal cancer.